Certainly not a stellar report but not all doom and gloom. They...

Certainly not a stellar report but not all doom and gloom.

They appear to be burning $1.3M per quarter so have been quite economical to last this long with the $9.5M cash injection from EBOS.

No revenue through MedExpress yet (disappointing).

The Adheris partnership suggests a small scale rollout to select Adheris pharmacies, noting small scale is the size of the entire pharmacy market in AU, before rolling out to all the Adheris chain.

Hopefully with the payment feature just announced and the revenue from international opportunities they may be CFP by the end of H1 FY20.

I suspect EBOS is committed to the success of MedAdvisor so can top up the kitty (if needed) as we get closer to the international revenues.

I would hate to see a CR and further dilution before the year is out. This is unlikely to happen as Management and insiders hold so much of the register so would only be diluting themselves.

I am again disappointed in the delay in realising revenue from MedExpress and Adheris. Both these partnerships were announced quite some time ago.